デフォルト表紙
市場調査レポート
商品コード
1317918

In Vivo CRO市場:タイプ別(非齧歯類、齧歯類)、GLPタイプ別(GLPトキシコロジー、非GLP)、適応症別-2023~2030年の世界予測

In Vivo CRO Market by Type (Non-Rodent, Rodent), GLP Type (GLP Toxicology, Non-GLP), Indication - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 199 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
In Vivo CRO市場:タイプ別(非齧歯類、齧歯類)、GLPタイプ別(GLPトキシコロジー、非GLP)、適応症別-2023~2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 199 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

In Vivo CROの世界市場は、2023年に44億6,617万米ドル、CAGR 9.68%で大きく成長し、2030年には85億6,651万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のIn Vivo CRO市場を評価するために不可欠です。ビジネス戦略と製品満足度の主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展:有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化:新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向:COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報:主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション:将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします:

1.In Vivo CROの世界市場規模および予測は?

2.予測期間中、世界のIn Vivo CRO市場を形成するCOVID-19の阻害要因と影響は?

3.In Vivo CROの世界市場において予測期間中に投資すべき製品/セグメント/用途/分野は?

4.In Vivo CROの世界市場における競争戦略は?

5.In Vivo CROの世界市場における技術動向と規制の枠組みは?

6.In Vivo CROの世界市場における主要ベンダーの市場シェアは?

7.In Vivo CROの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 経済的メリットによりアウトソーシングサービスの利用が増加
      • 官民セクターによる製薬調査への投資の拡大
      • バイオシミラー医薬品および医薬品の開発への注目の高まり
    • 抑制要因
      • 臨床試験プロセスに伴う高額なコスト
    • 機会
      • 臨床試験プロセスの世界化
      • 競合製薬分野での特許出願中
    • 課題
      • In vivo CROの品質管理に関する問題
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 In Vivo CRO市場:タイプ別

  • イントロダクション
  • 非齧歯類
  • 齧歯類
    • マウス
    • ネズミ

第7章 In Vivo CRO市場:GLPタイプ別

  • イントロダクション
  • GLPトキシコロジー
    • 社内
    • アウトソーシング
  • 非GLP
    • 社内
    • アウトソーシング

第8章 In Vivo CRO市場:適応症別

  • イントロダクション
  • 自己免疫/炎症状態
    • 過敏性腸症候群
    • 多発性硬化症
    • 変形性関節症
    • 関節リウマチ
  • 血液がん
  • 中枢神経系の状態
    • ALS
    • てんかん
    • ハンチントン病
    • 筋肉の再生
    • パーキンソン病
    • 脳卒中
    • 外傷性脳損傷
  • 糖尿病
  • 肥満
  • 腫瘍学
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛
  • 固形腫瘍
    • 患者由来の異種移植片
    • 同系モデル
    • 異種移植片

第9章 南北アメリカのIn Vivo CRO市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のIn Vivo CRO市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのIn Vivo CRO市場

  • イントロダクション
  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ分析:主要企業別

第13章 掲載企業一覧

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. IN VIVO CRO MARKET RESEARCH PROCESS
  • FIGURE 2. IN VIVO CRO MARKET SIZE, 2022 VS 2030
  • FIGURE 3. IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. IN VIVO CRO MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
  • FIGURE 5. IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2022 VS 2030 (%)
  • FIGURE 6. IN VIVO CRO MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
  • FIGURE 7. IN VIVO CRO MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. IN VIVO CRO MARKET DYNAMICS
  • FIGURE 9. IN VIVO CRO MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. IN VIVO CRO MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. IN VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. IN VIVO CRO MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. IN VIVO CRO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. IN VIVO CRO MARKET SIZE, BY NON-RODENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 7. IN VIVO CRO MARKET SIZE, BY RODENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. IN VIVO CRO MARKET SIZE, BY MICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. IN VIVO CRO MARKET SIZE, BY RATS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. IN VIVO CRO MARKET SIZE, BY IN HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. IN VIVO CRO MARKET SIZE, BY OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 16. IN VIVO CRO MARKET SIZE, BY NON-GLP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. IN VIVO CRO MARKET SIZE, BY IN HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. IN VIVO CRO MARKET SIZE, BY OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 21. IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. IN VIVO CRO MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. IN VIVO CRO MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. IN VIVO CRO MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. IN VIVO CRO MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. IN VIVO CRO MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 28. IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. IN VIVO CRO MARKET SIZE, BY ALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. IN VIVO CRO MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. IN VIVO CRO MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. IN VIVO CRO MARKET SIZE, BY MUSCLE REGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. IN VIVO CRO MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. IN VIVO CRO MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. IN VIVO CRO MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. IN VIVO CRO MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. IN VIVO CRO MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. IN VIVO CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 40. IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. IN VIVO CRO MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. IN VIVO CRO MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 44. IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. IN VIVO CRO MARKET SIZE, BY PATIENT-DERIVED XENOGRAFT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. IN VIVO CRO MARKET SIZE, BY SYNGENEIC MODEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. IN VIVO CRO MARKET SIZE, BY XENOGRAFT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 322. NETHERLANDS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 324. NETHERLANDS IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 332. NIGERIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. NIGERIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 334. NIGERIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. NIGERIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 338. NIGERIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 340. NIGERIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 341. NIGERIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 342. NORWAY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 343. NORWAY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 344. NORWAY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 345. NORWAY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 348. NORWAY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 350. NORWAY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 351. NORWAY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 352. POLAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 353. POLAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 354. POLAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 355. POLAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 356. POLAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 357. POLAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 358. POLAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 359. POLAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 360. POLAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 361. POLAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 362. QATAR IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 363. QATAR IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 364. QATAR IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 365. QATAR IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 366. QATAR IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 367. QATAR IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 368. QATAR IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 369. QATAR IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 370. QATAR IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 371. QATAR IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 372. RUSSIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 373. RUSSIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 374. RUSSIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 375. RUSSIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 376. RUSSIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 377. RUSSIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 378. RUSSIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 379. RUSSIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 380. RUSSIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 381. RUSSIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 382. SAUDI ARABIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (
目次
Product Code: MRR-0D217D5AEECD

The Global In Vivo CRO Market is forecasted to grow significantly, with a projected USD 4,466.17 million in 2023 at a CAGR of 9.68% and expected to reach a staggering USD 8,566.51 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global In Vivo CRO Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global In Vivo CRO Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Non-Rodent and Rodent. The Rodent is further studied across Mice and Rats. The Non-Rodent is projected to witness significant market share during forecast period.

Based on GLP Type, market is studied across GLP Toxicology and Non-GLP. The GLP Toxicology is further studied across In House and Outsourcing. The Non-GLP is further studied across In House and Outsourcing. The Non-GLP is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Autoimmune/inflammation conditions, Blood Cancer, CNS conditions, Diabetes, Obesity, Oncology, Pain management, and Solid Tumor. The Autoimmune/inflammation conditions is further studied across Irritable Bowel Syndrome, Multiple Sclerosis, Osteoarthritis, and Rheumatoid Arthritis. The CNS conditions is further studied across ALS, Epilepsy, Huntington's Disease, Muscle Regeneration, Parkinson's Disease, Stroke, and Traumatic Brain Injury. The Pain management is further studied across Acute Pain and Chronic Pain. The Solid Tumor is further studied across Patient-derived Xenograft, Syngeneic Model, and Xenograft. The Pain management is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global In Vivo CRO Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global In Vivo CRO Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global In Vivo CRO Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global In Vivo CRO Market?

4. What is the competitive strategic window for opportunities in the Global In Vivo CRO Market?

5. What are the technology trends and regulatory frameworks in the Global In Vivo CRO Market?

6. What is the market share of the leading vendors in the Global In Vivo CRO Market?

7. What modes and strategic moves are considered suitable for entering the Global In Vivo CRO Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. In Vivo CRO Market, by Type, 2022 vs 2030
  • 4.3. In Vivo CRO Market, by GLP Type, 2022 vs 2030
  • 4.4. In Vivo CRO Market, by Indication, 2022 vs 2030
  • 4.5. In Vivo CRO Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing usage of outsourcing services due to economic benefits
      • 5.1.1.2. Growing investments in the pharmaceutical research by public and private sectors
      • 5.1.1.3. Rising focus on the development of biosimilar medicines and drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the clinical trial processes
    • 5.1.3. Opportunities
      • 5.1.3.1. Globalization of clinical trial processes
      • 5.1.3.2. Competitive landscape in the pharmaceutical sector with patent applications
    • 5.1.4. Challenges
      • 5.1.4.1. Issues related to quality control in In vivo CROs
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. In Vivo CRO Market, by Type

  • 6.1. Introduction
  • 6.2. Non-Rodent
  • 6.3. Rodent
    • 6.3.1. Mice
    • 6.3.2. Rats

7. In Vivo CRO Market, by GLP Type

  • 7.1. Introduction
  • 7.2. GLP Toxicology
    • 7.2.1. In House
    • 7.2.2. Outsourcing
  • 7.3. Non-GLP
    • 7.3.1. In House
    • 7.3.2. Outsourcing

8. In Vivo CRO Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune/inflammation conditions
    • 8.2.1. Irritable Bowel Syndrome
    • 8.2.2. Multiple Sclerosis
    • 8.2.3. Osteoarthritis
    • 8.2.4. Rheumatoid Arthritis
  • 8.3. Blood Cancer
  • 8.4. CNS conditions
    • 8.4.1. ALS
    • 8.4.2. Epilepsy
    • 8.4.3. Huntington's Disease
    • 8.4.4. Muscle Regeneration
    • 8.4.5. Parkinson's Disease
    • 8.4.6. Stroke
    • 8.4.7. Traumatic Brain Injury
  • 8.5. Diabetes
  • 8.6. Obesity
  • 8.7. Oncology
  • 8.8. Pain management
    • 8.8.1. Acute Pain
    • 8.8.2. Chronic Pain
  • 8.9. Solid Tumor
    • 8.9.1. Patient-derived Xenograft
    • 8.9.2. Syngeneic Model
    • 8.9.3. Xenograft

9. Americas In Vivo CRO Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific In Vivo CRO Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa In Vivo CRO Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing